Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases

International Journal of Neuroscience

Volumn 127, Issue 4, 2017, Pages 368-375

  Han, Jie ^a,b   Wang, Miaomiao ^c   Ren, Manru ^a   Lou, Haiyan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

DAP12; microglia; neurological diseases; TREM2

Indexed keywords

TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TREM2 PROTEIN, HUMAN; TYROBP PROTEIN, HUMAN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; FRONTOTEMPORAL DEGENERATION; HUMAN; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHAGOCYTOSIS; POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; METABOLISM; MICROGLIA; NERVOUS SYSTEM DISEASES; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICROGLIA; NERVOUS SYSTEM DISEASES; RECEPTORS, IMMUNOLOGIC;

EID: 85011355710     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207454.2016.1264072     Document Type: Review

References (83)

1. Colonna M., TREMs in the immune system and beyond. Nat Rev Immunol 2003;3(6):445–53.
2. Schmid CD, Sautkulis LN, Danielson PE, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 2002;83(6):1309–20.
3. Colonna M, Turnbull I, Klesney-Tait J. The enigmatic function of TREM-2 in osteoclastogenesis. Osteoimmunology Springer US 2007;602:0065–2598.
4. Bouchon A, Hernández-Munain C, Cella M, et al. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 2001;194(8):1111–22.
5. Sessa G, Podini P, Mariani M, et al. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 2004;20(10):2617–28.
6. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006;7(12):1266–73.
7. Daws MR, Lanier LL, Seaman WE, et al. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 2001;31(3):783–91.
8. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009;21(1):38–46.
9. Jiang T, Yu JT, Zhu XC, et al. TREM2 in Alzheimer's disease. Mol Neurobiol 2013;48(1):180–85.
10. Golde TE, Streit WJ, Chakrabarty P. Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's. Alzheimer's Res Therapy 2013;5(3):24–24.
11. Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005;201(4):647–57.
12. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in trem2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurolog 2013;70(1):78–84.
13. Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds Apolipoprotein E. J Biol Chem 2015;290(43):26033–42.
14. Chan G, White CC, Winn PA, et al. CD33 modulates TREM2:convergence of Alzheimer loci. Nat Neurosci 2015;18:1556–8.
15. Schmid CD, Sautkulis LN, Danielson PE, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 2002;83(6):1309–20.
16. Hamerman JA, Tchao NK, Lowell CA, et al. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunolog 2005;6(6):579–86.
17. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunolog 2009;21(1):38–46.
18. Otero K, Turnbull IR, Poliani PL, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and β-catenin. Nat Immunolog 2009;10(7):734–43.
19. Peng Q, Long CL, Malhotra S, et al. A physical interaction between the adaptor proteins DOK3 and DAP12 is required to inhibit lipopolysaccharide signaling in macrophages. Sci Signaling 2013;6(289):ra72.
20. Turnbull IR, Gilfillan S, Cella M, et al. Cutting edge:TREM-2 attenuates macrophage activation. J Immunolog 2006;177(6):3520–4.
21. Hamerman JA, Jarjoura JR, Humphrey MB, et al. Cutting edge:inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunolog 2006;177(4):2051–5.
22. Peng Q, Malhotra S, Torchia JA, et al. TREM2-and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signaling 2009;3(122):ra38–ra38.
23. Linnartz B, Wang Y, Neumann H. Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int JAlzheimer's Dis 2009;2010:1703–10.
24. Hsieh CL, Koike M, Spusta SC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 2009;109(4):1144–56.
25. Otero K, Shinohara M, Zhao H, et al. TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunolog 2012;188(6):2612–21.
26. Satoh J, Kawana N, Yamamoto Y, et al. A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer's brain tissues. Alzheimer's Res Therapy 2013;5(4):30–30.
27. Rosenthal SL, Kamboh MI. Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr Genet Med Rep 2014;2(2):85–101.
28. Melchior B, Garcia AE, Hsiung BK, et al. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice:implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2009;2(3):e00037–e00037.
29. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. New Engl J Med 2013;368(2):107–16.
30. Jiang T, Tan L, Zhu XC, et al. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol Aging 2015;36(12):3176–86.
31. Ulrich JD, Finn MB, Wang Y, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 2014;9(1):20.
32. Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 2015;212(3):287–95.
33. Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimer's Dis:JAD 2012;35(1):45–9.
34. Abduljaleel Z, Al-Allaf FA, Khan W, et al. Evidence of TREM2 variant associated with triple risk of Alzheimer's disease. PloS One 2014;9(3):e92648–e92648.
35. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. New Engl J Med 2013;368(2):117–27.
36. Korvatska O, Leverenz JB, Jayadev S, et al. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family:clinical, genetic, and neuropathological study. JAMA Neurolog 2015;72(8):920–7.
37. Carrasquillo MM, Barber I, Lincoln SJ, et al. Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiol Aging 2016;37:38–44.
38. Lue LF, Schmitz CT, Serrano G, et al. TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Patholog 2015;25(4):469–80.
39. Zhao Y, Bhattacharjee S, Jones BM, et al. Regulation of TREM2 expression by an NF-кB-sensitive miRNA-34a. Neuroreport 2013;24(6):318–23.
40. Lue LF, Schmitz CT, Serrano G, et al. TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Patholog 2015;25(4):469–80.
41. Mori Y, Yoshino Y, Ochi S, et al. TREM2 mRNA expression in Leukocytes is increased in Alzheimer's disease and Schizophrenia. PloS One 2015;10(9):e0136835–e0136835.
42. Paloneva J, Mandelin J, Kiialainen A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003;198(4):669–75.
43. Verloes A, Maquet P, Sadzot B, et al. Nasu-Hakola syndrome:polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J Med Genet 1997;34(9):753–7.
44. Bianchin MM, Capella HM, Chaves DL, et al. Nasu-Hakola disease (Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy-PLOSL):a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 2004;24(1):1–24.
45. Verloes A, Maquet P, Sadzot B, et al. Nasu-Hakola syndrome:polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J Med Genet 1997;34(9):753–7.
46. Klünemann HH, Ridha BH, Magy L, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts DAP12 and TREM2. Neurolog 2005;64(9):1502–7.
47. Autti T, Raininko R, Partanen J, et al. CNS manifestations of Nasu–Hakola disease a frontal dementia with bone cysts. Neurolog 2001;56(11):1552–8.
48. Kaifu T, Nakahara J, Inui M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clinical Investigation 2003;111(3):323–323.
49. Nataf S, Anginot A, Vuaillat C, et al. Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Amer J Patholog 2005;166(1):275–86.
50. Paloneva J, Kestilä M, Wu J, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000;25(3):357–61.
51. Kiialainen A, Hovanes K, Paloneva J, et al. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis 2005;18(2):314–22.
52. Soragna D, Tupler R, Ratti MT, et al. An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. J Neurolog, Neurosurgery & Psychiatry 2003;74(6):825–6.
53. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Amer J Hum Genet 2002;71(3):656–62.
54. Nylander PO, Drugge U, Holmgren G, et al. Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLO-SL):a genealogical study of Swedish families of probable Finnish background. Clinical Genet 1996;50(5):353–7.
55. Edvardsen P, Halvorsen TB, Nesse O. Lipomembranous osteodysplasia:a case report. Int Orthopaedics 1983;7(2):99–103.
56. Bird TD, Koerker RM, Leaird BJ, et al. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease) a genetic cause of presenile dementia. Neurolog 1983;33(1):81–81.
57. Park JS, Ji IJ, An HJ, et al. Disease-associated mutations of TREM2 alter the processing of N‐linked Oligosaccharides in the Golgi Apparatus. Traffic 2015;16(5):510–8.
58. Kremenchutzky M, Baskerville J, Cottrell DA, et al. Progressive-relapsing and relapsing-progressive multiple sclerosis:a reevaluation. Mult Sclerosis 1998;4:372.
59. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3(4):291–301.
60. Hohlfeld R, Wekerle H. Drug insight:using monoclonal antibodies to treat multiple sclerosis. Nat Clinical Pract Neurolog 2005;1(1):34–44.
61. Poliani PL, Wang Y, Fontana E, et al. TREM2 sustains microglial expansion during aging and response to demyelination. J Clinical Investigation 2015;125(125 (5)):2161–70.
62. Elliott R, Li F, Dragomir I, et al. Analysis of the host transcriptome from demyelinating spinal cord of murine coronavirus-infected mice. PloS One 2012;8(9):e75346–e75346.
63. Matthews AE, Weiss SR, Paterson Y. Murine hepatitis virus—a model for virus-induced CNS demyelination. J Neurovirolog 2002;8(2):76–85.
64. Takahashi K, Prinz M, Stagi M, et al. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 2007;4(4):e124–e124.
65. Kim H, Walczak P, Kerr C, et al. Immunomodulation by transplanted human embryonic stem cell-derived oligodendroglial progenitors in experimental autoimmune encephalomyelitis. Stem Cells 2012;30(12):2820–9.
66. Piccio L, Buonsanti C, Mariani M, et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunolog 2007;37(5):1290–1301.
67. Mayeux R., Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26(1):81–104.
68. Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease:neurodegenerative mechanisms and neuroprotective interventions—report of a workshop. Movement Disorders 1998;13(5):759–67.
69. Jellinger KA., Neuropathology of dementia disorders. J Alz Dis Parkinsonism 2014;4:1–1.
70. Spillantini MG, Crowther RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci 1998;95(11):6469–73.
71. Croisier E, Moran LB, Dexter DT, et al. Microglial inflammation in the parkinsonian substantia nigra:relationship to alpha-synuclein deposition. J Neuroinflammation 2005;2:14–14.
72. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration:evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegeneration 2013;8(1):1–5.
73. Feng S, Nie K, Gan R, et al. Triggering receptor expressed on myeloid cells 2 variants are rare in Parkinson's disease in a Han Chinese cohort. Neurobiol Aging 2014;35(7):1780.e11–1780.e12.
74. Liu G, Liu Y, Jiang Q, et al. Convergent genetic and expression datasets highlight TREM2 in Parkinson's disease susceptibility. Mol Neurobiol 2015;2015:1–8.
75. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in trem2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurolog 2013;70(1):78–84.
76. Varvel NH, Grathwohl SA, Baumann F, et al. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci 2012;109(44):18150–5.
77. Guerreiro R, Bilgic B, Guven G, et al. A novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging 2013;34(12):2890.e1–2890.e5.
78. Le Ber I, De Septenville A, Guerreiro R, et al. Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol Aging 2014;35(10):2419. e23–2419. e25.
79. Beal CC., Gender and stroke symptoms:a review of the current literature. J Neurosci Nursing 2010;42(2):80–7.
80. Mattson MP, Duan W, Pedersen W A, et al. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 2001;6(1–2):69–81.
81. Kawabori M, Kacimi R, Kauppinen T, et al. Triggering receptor expressed on Myeloid Cells 2 (TREM2) deficiency Attenuates Phagocytic activities of Microglia and Exacerbates Ischemic damage in experimental stroke. J Neurosci 2015;35(8):3384–96.
82. Sieber MW, Jaenisch N, Brehm M, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PloS One 2012;8(1):e52982.
83. Kawabori M, Hokari M, Zheng Z, et al. Triggering receptor expressed on myeloid cells-2 correlates to hypothermic neuroprotection in ischemic stroke. Therapeutic Hypothermia Temperature Manag 2013;3(4):189–98.